Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  LexaGene Holdings Inc.    LXG   CA52886L1031

LEXAGENE HOLDINGS INC.

(LXG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

LexaGene : Engages Tailwinds Research Group

share with twitter share with LinkedIn share with facebook
09/18/2020 | 06:01pm EDT

BEVERLY, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has engaged Tailwinds Research Group to provide digital content distribution for the Company.

LexaGene engaged Tailwinds for a 1-year term, at $2,500/month USD with 100,000 stock options provided at $0.88 CAD/option.

In addition, LexaGene granted a non-executive Director 350,000 options at $0.66 CAD/option to replace options priced at $0.33 CAD/option that had expired on June 27, 2020. LexaGene also granted a second non-executive Director 170,000 restricted share units (RSUs) to replace an equal number of RSUs that expired on September 12, 2020.

To be added to the LexaGene email list, please subscribe on the Company website.

On Behalf of the Board of Directors
Dr. Jack Regan
Chief Executive Officer & Director

About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

For further information, please contact:

Media Contacts
Nicole Ridgedale
Director of Corporate Marketing, LexaGene
800.215.1824 ext 206
nridgedale@lexagene.com

Investor Relations
Jay Adelaar
Vice President of Capital Markets, LexaGene
800.215.1824 ext 207
jadelaar@lexagene.com

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Lexagene-logo_srgb_1000px.jpg

Source: LexaGene Holdings Inc

2020 GlobeNewswire, Inc., source Press Releases


share with twitter share with LinkedIn share with facebook
All news about LEXAGENE HOLDINGS INC.
10/05LEXAGENE : Provides a Corporate Update
AQ
10/05LexaGene Provides a Corporate Update
GL
09/21LexaGene's CEO Provides Video Message on Company's Progress and Announces App..
GL
09/21LEXAGENE : CEO Provides Video Message on Company's Progress and Announces Appoin..
AQ
09/18LEXAGENE : Engages Tailwinds Research Group
AQ
09/18LexaGene Engages Tailwinds Research Group
GL
09/09LEXAGENE : Announces Closing of CAD$13.29 Million Financing
AQ
08/19LEXAGENE : IIROC Trading Resumption - LXG
AQ
08/19LEXAGENE : Announces an Increase to Previously Announced Bought Deal Public Offe..
AQ
08/19LEXAGENE : IIROC Trading Halt - LXG
AQ
More news
Financials (USD)
Sales 2021 5,20 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 62,2 M 62,5 M -
Capi. / Sales 2021 12,0x
Capi. / Sales 2022 4,61x
Nbr of Employees 26
Free-Float 89,2%
Chart LEXAGENE HOLDINGS INC.
Duration : Period :
LexaGene Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEXAGENE HOLDINGS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 1,93 CAD
Last Close Price 0,72 CAD
Spread / Highest target 200%
Spread / Average Target 168%
Spread / Lowest Target 136%
Managers
NameTitle
Jack Regan Chairman & Chief Executive Officer
Daryl Rebeck President & Non-Independent Director
Steven Armstrong Senior Director-Operations
Jeffrey Mitchell Chief Financial Officer & Secretary
Tom Slezak Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LEXAGENE HOLDINGS INC.-18.18%65
EXACT SCIENCES CORPORATION15.24%16 003
GUARDANT HEALTH, INC.31.69%10 251
BGI GENOMICS CO., LTD.95.88%7 942
ADAPTIVE BIOTECHNOLOGIES CORPORATION66.95%6 783
INVITAE CORPORATION185.68%6 073